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Background: During the past decades, numerous efforts have been made to decrease the death rate among lung
cancer patients. Nonetheless, the improvement in long-term survival has been limited and lung cancer is still a
devastating disease.
Discussion: With this article we would like to point out that survival of lung cancer could be strongly improved by
controlling two pivotal prognostic factors: stage and treatment. This is corresponding with recent reports that show
a decrease in lung cancer mortality by screening programs. In addition, modulation of the patient’s immune system
by immunotherapy either as monotherapy or combined with conventional cancer treatments offers the prospect of
tailoring treatments much more precisely and has also been shown to lead to a better response to treatment and
overall survival of non-small cell lung cancer patients.
Summary: Since only small improvements in survival can be expected in advanced disease with the use of
conventional therapies, more research should be focused on lung cancer screening programs and patient tailored
immunotherapy with or without conventional therapies. If these approaches are clinically combined in a standard
multidisciplinary policy we might be able to advance the survival of patients with lung cancer.
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Lung cancer is the leading cause of cancer-related death
worldwide. Approximately 85% of all cases of lung cancer
are non–small cell lung cancer (NSCLC). The 5-year
survival of this aggressive disease is only 16% [1]. One of
the reasons for this extremely poor survival is that most
lung cancer cases are diagnosed at an advanced stage due
to the relative lack of clinical symptoms during early stages.
Metastatic NSCLC is currently an incurable disease for
which standard chemotherapy provides only minor im-
provement in overall survival. In addition, less than 30% of
patients with advanced-stage NSCLC have a response to
platinum-based chemotherapy, the most commonly used
first line treatment at this stage of the disease [2].
During the last decades, advances in diagnostic and
therapeutic approaches of this devastating disease have
been made, however, long-term survival rates have hardly
changed in the past 50 years [3]. Therefore, new approaches
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Survival of lung cancer could be strongly improved by con-
trolling two pivotal prognostic factors: stage and treatment.
Early stages of lung cancer have a better prognosis; thus
early diagnosis of lung cancer by screening programs is one
way that leads to a reduction in lung cancer mortality.
However, given the high chance of tumor recurrence, even
alleged early stage NSCLC patients with adequate surgical
resection can have undetectable metastases at diagnosis
[4,5]. It is known that adjuvant chemotherapy can reduce
these metastases; nevertheless, in 24% of the patients me-
tastasis occurs after adjuvant chemotherapy [4]. Therefore,
besides lung cancer screening programs, an additional
approach next to the conventional therapy must be devel-
oped to tackle lung cancer. In recent years it has been
established that the immune system plays an important role
in carcinogenesis and makes an essential contribution to
the anti-tumor effects of traditional therapies. Modulation
of the patient’s immune system by immunotherapy either
as monotherapy or combined with conventional cancer
treatments offers the prospect of tailoring treatments much
more precisely and could lead to a better response to treat-
ment and overall survival of NSCLC patients.l Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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programs and patient-tailored immunotherapy are com-
bined in a standard multidisciplinary policy for NSCLC
treatment, we might be able to advance the survival of
patients with early stage lung cancer. We will discuss
both topics and their role in improving lung cancer sur-
vival below.
Lung cancer screening
Multiple randomized trials have investigated the effective-
ness of lung cancer screening and it is shown that lung
cancer can be identified at an early stage with detection
rates varying between 40-66% [6,7]. The survival rates of
lung cancer patients diagnosed in screening programs are
very high; 5- and even 10-year survival rates close to 90%
can be achieved [8,9]. The largest lung cancer screening
trial [10] recently showed that screening of high risk per-
sons is very effective in reducing the mortality from lung
cancer. Persons with more than 30 pack-years (PY) and
aged between 55 and 74 years at time of randomization
were included in this study. They found a relative mortality
reduction of 20% when this high-risk group is screened
with a low-dose computer tomography (CT) scan com-
pared to chest radiography [10]. However, this is probably
an underestimate, as the mortality reduction was measured
at the time of closure of the trial. The introduction of low-
dose multi-detector CT has led to important advantages,
such as advanced scan speed, better spatial resolution, and
the capacity to reconstruct multiple series from a single
data acquisition. Before public policy recommendations are
crafted, there are major concerns in lung cancer screening
such as the effects of false positive findings, lead-time bias,
the impact of overdiagnosis, and the generalizability of the
results [11].
Another important aspect that should be considered in
generalizing the results of screening studies are the thera-
peutic options for patients with a positive screening, as
lung cancer treatment is an important prognostic factor. In
developed countries, lung cancer patients are treated with
surgery, chemotherapy, and radiotherapy. In recent years,
peri-operative mortality has decreased by the introduction
of video assisted thoracoscopy (VATS) and better peri-
operative management [12]. Early stage patients who are
not eligible for surgery are frequently treated with radio-
therapy with curative intent. Novel radiotherapy techni-
ques, such as stereotactic ablative radiotherapy, show local
control rates of 90% or more for stage I NSCLC [13]. Adju-
vant chemotherapeutic regimens have been shown to
increase survival especially in resected patients with stage
II and IIIA disease [14]. These regimens are expensive and
therefore the results of the published screening trials can
only be applied to the selected group of individuals in
countries with well-developed health care systems with a
quality comparable to the US.Adjuvant immunotherapy
Treatment of lung cancer is currently based on the patient’s
clinical signs and symptoms, tumor stage and subtype,
medical history, and data from imaging and laboratory
evaluation. Until now, most cancer research is focused on
therapies based on tumor characteristics to improve the
prognosis of NSCLC, as cancer has long been considered
as a cell-autonomous genetic disease. However, the sobe-
ring outcome of current NSCLC therapy has shifted the
attention to combining adjuvant treatment approaches.
Recent experimental findings and clinical observations
have led to cancer-related immune inflammation being
acknowledged as a new hallmark of cancer [15-17]. Evi-
dence that the immune system of the host can influence
cancer incidence, cancer growth, response to therapy, and
the prognosis of the disease, is growing [18]. Therefore it
was thought that conventional therapy combined with
immunotherapy based on a pretreatment profile of the
immune system of the host could be a valuable tool to
increase the survival of early stage NSCLC [19].
Cancer immunotherapy attempts to activate the host’s
immune system to recognize and destroy the residual lung
cancer cells that conventional therapy misses. Immuno-
therapy can be divided into two main types: passive and
active immunotherapy [20,21]. The most common form
of passive immunotherapy is monoclonal antibody
therapy [20]. It makes use of antibodies that have been
produced in vitro and can bind to specific cell surface
proteins that can influence tumor growth [22]. How-
ever, there will only be a response of the immune system
during the time the antibody is present in the body. Ipili-
mumab (anti-CTLA-4), bevacizumab (anti-VEGF), and
anti programmed death (anti-PD-1) or anti-PD ligand 1
(Anti-PD-L1) are examples of passive immunotherapy
that could be useful in NSCLC [23-26].
Ipilimumab blocks the negative cytotoxic T-lymphocyte
antigen (CTLA)-4 that enhances T-cell responses to
tumor cells, leading to effective immune responses. For
NSCLC, ipilimumab is now in phase II development [24],
but it is already approved by the US Food and Drug
Administration (FDA) for the treatment of unresectable or
metastatic melanoma [24,27,28]. Studies show that the two-
and three-year survival rates in ipilimumab-containing
treatment arms in metastatic melanoma patients are almost
twice as high as in the non-ipilimumab-containing treat-
ment arm.
Bevacizumab is an antibody that neutralizes the vascular
endothelial growth factor (VEGF) ligand. As a result, it will
inhibit angiogenesis [29]. Moreover, research has shown
that adding bevacizumab to chemotherapy is associated
with afferent vascular dilatation and efferent vascular con-
striction of tumor vessels that may help concentrate
chemotherapy at the tumor site. Bevacizumab combined
with taxane-platinum chemotherapy is the first approved
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crease of progression-free survival and overall survival in
first-line treatment of stage IV NSCLC [29,30]. Recently,
data have been published on the immunogenic effect of
VEGF. VEGF seems to be involved in a number of mecha-
nisms negatively influencing the immune system; it makes
dendritic cells more tolerogenic, and induces myeloid
derived suppressor cells. Adding bevacizumab prevents
immunotolerance and could thereby contribute to a better
survival of lung cancer [31,32].
Two other recently described antibodies that could play
important roles in passive immunotherapy are anti-PD-1
and anti-PD-L1 [25,26]. PD-1 is a co-inhibitory receptor on
activated T-cells that plays an important role in immuno-
suppression. PD-L1, the ligand of PD-1, is expressed on
cancer cells and is involved in negative regulation of im-
mune responses, as they increase apoptosis of T-cells and
inhibit CD4 and CD8 T-cell activation [25,26]. Inhibition of
the interaction between PD-1 and PD-L1 can improve
T-cell responses and mediate antitumor activity. Recent
studies show that in NSCLC the objective response rates to
anti-PD-1 and anti-PD-L1 are 18% and 10% respectively
[25,26]. Blockage of both receptors induced durable
tumor regression and prolonged stabilization of the
disease. These findings confirm that the pathway be-
tween PD1 and PD-L1 could play an important role in
therapeutic intervention and that it causes an increase
in survival of lung cancer patients.
Active immunotherapy tries to persuade and boost im-
mune effector cells in vivo against tumor cells through the
administration of immune mediators capable of activating
the humoral (antibodies) and cellular (T cells) immune
system [33]. Therefore the duration of this broad response
persists for a long time, because of the immunologic me-
mory and it is less prone to antigen mutational responses
[33]. Currently, multiple trials are investigating the effec-
tiveness of different lung cancer vaccines [33-36]. In 2001,
one of the first synthetic lung cancer vaccines showed that
16 out of 65 patients had an immune response after vacci-
nation, and the median survival time was more than
doubled (30.6 months, instead of 13.3 months in controls)
[37]. After that, other tumor-antigens vaccines, such as
Wilms tumor antigen-1 and IDM-2101 were tested and
showed immunological responses and prolonged survival
in patients with lung cancer [21,36]. Next to synthetic vac-
cines there are trials that test dendritic cell (DC) vaccines
[34,38,39]. In DC vaccines, tumor associated antigens are
used to load immature autologous DCs. These DCs are
injected into patients to stimulate antigen-specific immune
responses in lung cancer patients. Different studies have
shown biological activity of DC vaccines and phase I and II
trials report that a group of lung cancer patients had thera-
peutic benefit [34,39,40]. Nevertheless, until now, reports
about clinical applicability are anecdotal.Other examples of active immunotherapy in lung can-
cer are natural killer (NK) cell transfer and adoptive T
cell transfer [41,42].
As described above, recent literature provides evidence
for many potentially useful immunotherapy combinations.
However, these therapies show drastic antitumor
responses in only small subsets of patients. Currently,
there is lack of predictive biomarkers to rationally choose
combinations of immunotherapy for individual patients
that benefit from these therapies. Therefore, it is necessary
to further elucidate the mechanisms that are responsible
for clinical benefit in small groups of patients and identify
relevant pre-treatment biomarkers that distinguish
responders from non-responders. This patient-tailored
treatment approach is able to redress the balance towards
efficacious antitumor responses that can improve the over-
all survival for more patients.
Taken together, passive and active immunotherapy
might have an important adjuvant role in early stage
NSCLC by consolidating responses to conventional
therapy and thereby leading to increased lung cancer
survival rates. However, further research in this field is
warranted to improve these therapies and to define sub-
sets of responders.
Summary
During the past decades, numerous efforts have been
made to decrease the death rate among lung cancer
patients. Nonetheless, the improvement in long-term
survival has been limited and lung cancer is still a devas-
tating disease [3].
Since only small improvements in survival can be
expected in advanced disease with the use of conven-
tional therapies, more research should be focused on
early stage lung cancer. Combining lung cancer screen-
ing programs and patient tailored immunotherapy with
or without conventional therapies should be further
explored. If these approaches are clinically combined in
a standard multidisciplinary policy we might be able to
advance the survival of patients with lung cancer.
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